Abstract
Silymarin is the active constituent of Silybum marianum (milk thistle) which is a C-25 containing flavonolignan. Milk thistle has a lot of traditional values, being used as a vegetable, as salad, as bitter tonic, and as galactogogue in nursing mothers and in various ailments such as liver complications, depression, dyspepsia, spleenic congestions, varicose veins, diabetes, amenorrhea, uterine hemorrhage, and menstrual problems. In this present chapter, a comprehensive attempt has been made to discuss the potential of silymarin in chronic disorders. An insight into modulation of cellular signaling by silymarin and its implication in various disorders such as liver disorders, inflammatory disorders, cancer, neurological disorders, skin diseases, and hypercholesterolemia is being provided.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Pradhan SC, Girish C (2006) Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Ind J Med Res 124:491–504
Luper S (1998) A review of plants used in the treatment of liver diseases: Part 1. Altern Med Rev 3:410–421
Pepping J (1999) Milk thistle: Silybum marianum. Am J Health Syst Pharm 56:1195–1197
Barceloux DG (2008) Medical toxicology of natural substances. Wiley, New Jersey
Hackett ES, Twedt DC, Gustafson DL (2013) Milk thistle and its derivative compounds: a review of opportunities for treatment of liver disease. J Vet Intern Med 27:10–16
Morazzoni P, Montalbetti A, Malandrino S et al (1993) Comparative pharmacokinetics of silipide and silymarin in rats. Eur J Drug Metab Pharmacokinet 18:289–297
Ruzickowa G, Fojlova J, Souckova M (2011) Silybum marianum (L.) Gaertn. Seed oil from the perspective of environment and genotype- a pilot study. Acta Fytotechnica Zootechnica 14:9–12
Goli SAH, Kadivar M, Bahrami B, Sabzalian MR (2008) Physical and chemical characteristics of Silybum marianum seed oil. Iran J Food Sci Technol 4:27–32
Khan I, Khattak HU, Ullah I, Bangash FK (2007) Study of physicochemical properties of Silybum marianum seed oil. J Chem Soc Pak 29:545–548
Pliskova M, Vondracek J, Kren V et al (2005) Effects of silymarin flavonolignans and synthetic silybin derivatives on estrogen and aryl hydrocarbon receptor activation. Toxicology 215:80–89
Zhu W, Zhang JS, Young YF (2001) Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP. Carcinogenesis 22:1399–1403
Krena V, Walterov D (2005) Silybin and silymarin—new effects and applications. Biomed Papers 149:29–41
Zhang SH, Morris ME (2003) Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 304:1258–1267
Zhang SZ, Morris ME (2003) Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. Pharm Res 20:1184–1191
Nguyen H, Zhang SZ, Morris ME (2002) Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. J Pharm Sci 92:250–257
Maser P, Vogel D, Schmid C et al (2001) Identification and characterization of trypanocides by functional expression of an adenosine transporter from Trypanosoma brucei in yeast. J Mol Med 79:121–127
Saliou C, Valacchi G, Rimbach G (2001) Assessing bioflavonoids as regulators of NF-κB activity and inflammatory gene expression in mammalian cells. Meth Enzymol 335:380–386
Morishima C, Polyak SJ, Lohmann V et al (2010) Identification of hepatoprotective flavonolignans from silymarin. Proc Natl Acad Sci U S A 107:5995–5999
Yoo HG, Jung SN, Hwang YS et al (2004) Involvement of NF-κB and caspases in silibinin-induced apoptosis of endothelial cells. Int J Mol Med 13:81–86
Sinnberg T, Menzel M, Kaesler S et al (2010) Suppression of casein kinase 1alpha in melanoma cells induces a switch in betacatenin signaling to promote metastasis. Cancer Res 70:6999–7009
Klaus A, Birchmeier W (2008) Wnt signalling and its impact on development and cancer. Nat Rev Cancer 8:387–398
Liu C, Li Y, Semenov M et al (2002) Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108:837–847
Hart M, Concordet JP, Lassot I et al (1999) The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr Biol 9:207–210
Tyagi A, Agarwal C, Agarwal R (2002) Inhibition of retinoblastoma protein (Rb) phosphorylation at serine sites and an increase in Rb-E2F complex formation by silibinin in androgen-dependent human prostate carcinoma LNCaP cells: role in prostate cancer prevention. Mol Cancer Ther 1:525–532
Agarwal R (2000) Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem Pharmacol 60:1051–1059
Wang JY, Chang CC, Chiang CC et al (2012) Silibinin suppresses the maintenance of colorectal cancer stem-like cells by inhibiting PP2A/AKT/mTOR pathways. J Cell Biochem 113:1733–1743
Singh RP, Agarwal R (2004) Prostate cancer prevention by silibinin. Curr Cancer Drug Targets 4:1–11
Pferschy-Wenzig EM, Atanasov AG, Malainer C et al (2014) Identification of Isosilybin A from milk thistle seeds as an agonist of peroxisome proliferator-activated receptor gamma. J Nat Prod 77:842–847
Prakash P, Singh V, Jain M et al (2014) Silymarin ameliorates fructose induced insulin resistance syndrome by reducing de novo hepatic lipogenesis in the rat. Eur J Pharmacol 727:15–28
Demirci B, Demir O, Dost T et al (2013) Treated effect of silymarin on vascular function of aged rats: dependant on nitric oxide pathway. Pharm Biol [Epub ahead of print]
Zhao F, Shi D, Li T et al (2015) Silymarin attenuates paraquat-induced lung injury via Nrf2-mediated pathway in vivo and in vitro. Clin Exp Pharmacol Physiol. doi:10.1111/1440-1681.12448. [Epub ahead of print]
Ferenci P, Dragosics B, Dittrich H et al (1989) Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 9:105–113
Muriel P, Mourelle M (1990) Prevention by silymarin of membrane alterations in acute CCl4 liver damage. J Appl Toxicol 10:275–279
Mayer KE, Myers RP, Lee SS (2005) Silymarin treatment of viral hepatitis: a systematic review. J Viral Hepatitis 12:559–567
Vargas-Mendoza N, Madrigal-Santillan E, Morales-Gonzalez A et al (2014) Hepatoprotective effect of silymarin. World J Hepatol 6:144–149
Loguercio C, Festi D (2011) Silybin and the liver: from basic research to clinical practice. World J Gastroenterol 17:2288–2301
Dixit N, Baboota S, Kohli K et al (2009) Silymarin: a review of pharmacological aspects and bioavailability enhancement approaches. Ind J Pharmacol 39:172–179
Dehmlow C, Erhard J, De Groot H (1996) Inhibition of kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 23:749–754
Dehmlow C, Murawski N, De Groot H (1996) Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cells. Life Sci 58:1591–1600
Manna SK, Mukhopadhyay A, Van NT et al (1999) Silymarin suppresses TNF-induced activation of NF-kB, c-Jun N-terminal kinase and apoptosis. J Immunol 163:6800–6809
Haddad Y, Vallerand D, Brault A et al (2011) Antioxidant and hepatoprotective effects of silibinin in a rat model of nonalcoholic steatohepatitis. Evid Based Complement Altern Med 1–10
Colturato CP, Constantin RP, Maeda AS Jr et al (2012) Chem Biol Interact 195:119–132
DerMarderosian A (2001) The reviews of natural products, 1st edn. Facts and Comparisons, St. Louis
Meeran SM, Katiyar S, Elmets CA et al (2006) Silymarin inhibits UV radiation induced immunosuppression through augmentation of interleukin-12 in mice. Mol Cancer Ther 7:1660–1668
Strazzabosco M (1999) Effects of silybinin on biliary lipid composition. J Hepatol 12:290–292
Bhattacharya S (2011) Milk thistle (Silybum marianum L. Gaert.) seeds in health. In: Preedy VR, Watson RR, Patel V (eds) Nuts and seeds in health and disease prevention, 1st edn. Academic Press (an imprint of Elsevier), London, Burlington, San Diego
Kshirsagar A, Ingawale D, Ashok P et al (2009) Silymarin: a comprehensive review. Pharmacognosy Rev 3:116–124
Kreeman V, Skottova N, Walterova D (1998) Silymarin inhibits the development of diet-induced hypercholesterolemia in rats. Planta Med 64:138–142
Gazak R, Walterova D, Kren V (2007) Silybin and silymarin—new and emerging applications in medicine. Curr Med Chem 14:315–338
Tyagi A, Agarwal C, Harrison G et al (2004) Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages. Carcinogenesis 25:1711–1720
Das S, Roy P, Auddy RG et al (2011) Silymarin nanoparticle prevents paracetamol-induced hepatotoxicity. Int J Nanomed 6:1291–1301
Jain A, Yadav A, Bozhkov AI et al (2011) Therapeutic efficacy of sylimarin and naringenin in reducing arsenic-induced hepatic damage in young rats. Ecotoxicol Environ Saf 74:607–614
Mohamed O, Salam EA, Saleem AA et al (2010) Hepatoprotective effects of the nitric oxide donor isosorbide-5-mononitrate alone and in combination with the natural hepatoprotectant, silymarin on carbon tetrachloride-induced hepatic injury in rats. Inflammopharmacology 18:87–94
Shaker E, Mahmoud H, Mnaa S (2010) Silymarin, the antioxidant component and Silybum marianum extracts prevent liver damage. Food Chem Toxicol 48:803–806
Das SK, Vasudevan DM. Protective effects of silymarin, a milk thistle (Silybum marianum) derivative on ethanol induced oxidative stress in liver. Indian J Biochem Biophys 43:306–311
Zhang W, Hong R, Tian T (2013) Silymarin’s protective effects and possible mechanisms on alcoholic fatty liver for rats. Biomol Ther (Seoul) 30:264–269
Ramakrishnan G, Lo Muzio L, Elinos-Baez CM et al (2009) Silymarin inhibited proliferation and induced apoptosis in hepatic cancer cells. Cell Prolif 42:229–240
Varghese L, Agarwal C, Tyagi A et al (2005) Silibinin efficacy against human hepatocellular carcinoma. Clin Cancer Res 11:8441–8448
Bhatia N, Zhao J, Wolf DM et al (1999) Inhibition of human carcinoma cell growth and DNA synthesis by silibinin, an active constituent of milk thistle: comparison with silymarin. Cancer Lett 147:77–84
Huang Q, Wu LJ, Tashiro S et al (2005) Silymarin augments human cervical cancer HeLa cell apoptosis via P38/JNK MAPK pathways in serum-free medium. J Asian Nat Prod Res 7:701–709
Sharma Y, Agarwal C, Singh AK et al (2001) Inhibitory effect of silibinin on ligand binding to erbB1 and associated mitogenic signaling, growth, and DNA synthesis in advanced human prostate carcinoma cells. Mol Carcinog 30:224–236
Katiyar SK, Korman NJ, Mukhtar H et al (1997) Protective effects of silymarin against photocarcinogenesis in a mouse skin model. J Natl Cancer Inst 89:556–566
Das SK, Mukherjee S, Vasudevan DM (2008) Medicinal properties of milk thistle with special reference to silymarin: an overview. Nat Prod Radiance 7:182–192
Chen PN, Hsieh YS, Chiou HL et al. Silibinin inhibits cell invasion through inactivation of both PI3K-Akt and MAPK signaling pathways. Chem Biol Interact 156:141–150
Wang MJ, Lin WW, Chen HL et al (2002) Silymarin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation. Eur J Neurosci 16:2103–2112
Sayyah M, Boostani H, Pakseresht S et al (2010) Comparison of Silybum marianum (L.) Gaertn. with fluoxetine in the treatment of obsessive-compulsive disorder. PNBP 34:362–365
Chlopeikova A, Psotova J, Miketova P et al (2004) Chemopreventive effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes. Part I. Silymarin and its flavonolignans. Phytotherapy Res 18:107–110
Zholobenko A, Modriansky M (2014) Silymarin and its constituents in cardiac preconditioning. Fitoterapia 97:122–132
Vereckei AS, Blazovics A, Gyorgy I et al (1993) The role of free radicals in the pathogenesis of amiodarone toxicity. J Cardiovasc Electrophysiol 4:161–177
Breschi MC, Martinotti E, Apostoliti F et al (2002) Protective effect of silymarin in antigen challenge- and histamin-induced bronchoconstriction in vivo guinea-pigs. Eur J Pharmacol 437:91–95
Soto C, Mena R, Luna J et al (2004) Silymarin induces recovery of pancreatic function after alloxan damage in rats. Life Sci 75:2167–2180
Kock HP, Bachner J, Loffler E (1985) Silymarin: potent inhibitor of cyclic AMP phosphodiesterase. Meth Find Exp Clin Pharmacol 7:409–413
Khan AQ, Khan R, Tahir M et al (2014) Silibinin inhibits tumor promotional triggers and tumorigenesis against chemically induced two-stage skin carcinogenesis in Swiss albino mice: possible role of oxidative stress and inflammation. Nutr Cancer 66:249–258
Katiyar SK (2002) Treatment of silymarin, a plant flavonoid, prevents ultraviolet light-induced immune suppression and oxidative stress in mouse skin. Int J Oncol 21:1213–1222
Soto C, Perez J, Garcia V et al (2010) Effect of silymarin on kidneys of rats suffering from alloxan-induced diabetes mellitus. Phytomedicine 17:1090–1094
Kaur G, Athar M, Alam MS (2010) Dietary supplementation of silymarin protects against chemically induced nephrotoxicity, inflammation and renal tumor promotion response. Invest New Drugs 28:703–713
Nazemian F, Karimi GH, Moatamedi M et al (2010) Effect of Silymarin administration on TNF-α serum concentration in peritoneal dialysis patients. Phytotherapy Res 24:1654–1657
Polyak SJ, Morishima C, Shuhart MC et al (2007) Inhibition of T-cell inflammatory cytokines, hepatocyte NF-Kappa B signaling and HCV infection by standardised silymarin. Gastroenterology 132:1925–1936
Al-Rasheed NM, Al-Rasheed NM, Faddah LM et al (2014) Potential impact of silymarin in combination with chlorogenic acid and/or melatonin in combating cardiomyopathy induced by carbon tetrachloride. Saudi J Biol Sci 21:265–274
Nabila EA, Hania NC, Noura SAZ et al (2010) Protective effect of silymarin on cisplatin-induced nephrotoxicity in rats. Pak J Nutr 9:624–636
Shahbazi F, Dashti-Khavidaki S, Khalili H et al (2012) Potential renoprotective effects of silymarin against nephrotoxic drugs: a review of literature. J Pharm Pharm Sci 15:112–123
Laekeman G, De Coster S, De Meyer K (2003) St. Mary’s thistle: an overview. J Pharm Belg 58:28–31
Muriel P, Garciapina T, Perez-Alvarez V et al (1992) Silymarin protects against paracetamol-induced lipid peroxidation and liver damage. J Appl Toxicol 12:439–442
Boigk G, Stroedter L, Herbst H et al (1997) Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 26:643–649
Skottova N, Krecman V (1998) Dietary silymarin improves removal of low density lipoproteins by the perfused rat liver. Acta Univ Palackianae Olomucensis Facultatitis Med 141:39–40
Neha, Kumar A, Jaggi AS et al (2014) Silymarin ameliorates memory deficits and neuropathological changes in mouse model of high-fat-diet-induced experimental dementia. Naunyn Schmiedebergs Arch Pharmacol 387:777–787
Soto CP, Perez BL, Favari LP et al (1998) Prevention of alloxan-induced diabetes mellitus in the rat by silymarin. Comp Pharmacol Toxicol 119:125–129
Cheng KC, Asakawa A, Li YX et al (2014) Silymarin induces insulin resistance through an increase of phosphatase and tensin homolog in wistar rats. PLOS ONE
Zi X, Mukhtar H, Agarwal R (1997) Novel cancer chemopreventive effects of a flavonoid antioxidant silymarin: inhibition of mRNA expression of an endogenous tumor promoter TNF alpha. Biochem Biophys Res Commun 239:334–339
De La Lastra CA, Martin MJ, Motilva V et al (1995) Gastroprotection induced by silymarin, the hepatoprotective principle of Silybum marianum in ischemia-reperfusion mucosal injury: role of neutrophils. Planta Med 61:116–119
Albrecht M (1992) Therapy of toxic liver pathologies with Legalon. Z Klin Med 47:87–92
Salhanick SD, Wax PM, Schneider SM, Tong TC et al (2008) Comparative treatment of alpha-amanitin poisoning with N-acetylcysteine, benzylpenicillin, cimetidine, thioctic acid, and silybin in a murine model. Ann Emerg Med 52:184–185
Feher J, Deak G, Muzes G et al (1989) Liver-protective action of silymarin therapy in chronic alcoholic liver diseases. Orv Hetil 130:2723–2727
Moscarella S, Giusit A, Marra F et al (1993) Therapeutic and antilipoperoxidant effects of silybin-phosphatidylcholine complex in chronic liver disease. Curr Ther Res 53:98–102
Magliulo E, Gagliardi B, Fiori GP (1978) Results of a double blind study on the effect of silymarin in the treatment of acute viral hepatitis, carried out at two medical centres. Med Klin 73:1060–1065
Nassuato G, Iemmolo RM, Strazzabosco M et al (1991) Effect of Silibinin on biliary lipid composition experimental and clinical study. J Hepatol 12:290–295
Velussi M, Cernigoi AM, De Monte A et al (1997) Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol 26:871–879
Lang I, Nekam K, Gonzalez-Cabello R et al (1990) Hepatoprotective and immunological effects of antioxidant drugs. Tokai J Exp Clin Med 15:123–127
Grossmann M, Hoermann R, Weiss M et al (1995) Spontaneous regression of hepatocellular carcinoma. Am J Gastroenterol 90:1500–1503
Feher J, Lang I, Nekam K et al (1990) In vivo effect of free radical scavenger hepatoprotective agents on superoxide dismutase (SOD) activity in patients. Tokai J Exp Clin Med 15:129–134
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Neha, Jaggi, A.S., Singh, N. (2016). Silymarin and Its Role in Chronic Diseases. In: Gupta, S., Prasad, S., Aggarwal, B. (eds) Drug Discovery from Mother Nature. Advances in Experimental Medicine and Biology, vol 929. Springer, Cham. https://doi.org/10.1007/978-3-319-41342-6_2
Download citation
DOI: https://doi.org/10.1007/978-3-319-41342-6_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-41341-9
Online ISBN: 978-3-319-41342-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)